Schrödinger Reports Q3 2026 Revenue Growth Driven by Software and Drug Discovery Milestones
Schrödinger (SDGR) reported third-quarter revenue of $64.5 million, a 19% increase year-over-year. This growth was fueled by both its software segment and drug discovery business, which benefited significantly from a milestone payment from Structure Therapeutics. While the company is transitioning customers from on-premises to hosted licensing models—a shift that creates temporary revenue recognition headwinds—hosted software revenue grew by 49%. The company demonstrated strong commercial momentum with Annual Contract Value (ACV) rising 17% to $44.7 million. Consequently, Schrödinger raised its full-year ACV guidance to a range of $222 million to $232 million and increased its drug discovery revenue guidance to between $75 million and $85 million. Despite these gains, the company reported a net loss of $37.7 million, primarily due to mark-to-market changes in public equity positions.
Tickers: $SDGR
Topics: Drug Discovery Financial Performance Revenue Growth Software Licensing